Published: September 23, 2026
A newly published international best-practices consensus provides updated guidance on one of the more advanced treatment options available for patients living with persistent atrial fibrillation (A-fib): hybrid convergent ablation.
Hybrid convergent ablation combines an epicardial surgical approach with an endocardial catheter-based approach in a single, coordinated treatment strategy. The consensus reinforces that this combined approach continues to be an important option for carefully selected patients with advanced persistent and long-standing persistent A-fib — particularly those who are unlikely to achieve lasting results from catheter ablation alone.
The study, “Combined Epicardial and Endocardial Ablation for Atrial Fibrillation: An Updated Best Practices Guide to Hybrid Convergent Procedures,” was published in Heart Rhythm O2 in July 2026. Co-authors included Norton Heart & Vascular Institute electrophysiologist Kent E. Morris, M.D., MBA; cardiothoracic surgeon Steven M. Peterson, M.D., and Tara U. Mudd, APRN, service line vice president of Norton Heart & Vascular Institute.
“The most important takeaway is that treating complex atrial fibrillation is truly a team effort,” Dr. Morris said. “Hybrid convergent ablation gives us another important option for patients with persistent atrial fibrillation, but the best outcomes come from an integrated approach — bringing electrophysiology, cardiac surgery and the patient together for treatment selection through long-term follow-up.”
The consensus is clear that patient selection is the most critical factor in achieving successful outcomes. Hybrid convergent ablation is best suited for patients with more advanced A-fib substrates, including those with:
Notably, the authors do not recommend the procedure as a first-line therapy for paroxysmal A-fib or for patients with relatively normal atrial anatomy, underscoring that this is a targeted option for more complex cases.
The publication reviews several key trials demonstrating that hybrid ablation outperforms catheter ablation alone in patients with advanced A-fib:
One of the strongest mechanistic arguments in the paper centers on the left atrial posterior wall, which plays a critical role in persistent A-fib but is notoriously difficult to treat from inside the heart alone. Endocardial lesions in this region may not be fully transmural, and the risk of esophageal injury limits how much energy can be safely delivered, often leading to reconnection over time.
The epicardial component of hybrid ablation addresses these limitations directly, allowing for more durable posterior wall lesions, improved transmurality and access to epicardial arrhythmogenic structures such as the ligament of Marshall, ganglionated plexi and other epicardial connections that endocardial-only approaches cannot reach.
The consensus places significant emphasis on the care model surrounding the procedure, not just the procedure itself. A dedicated multidisciplinary A-fib program should include a core team of an electrophysiologist, a cardiothoracic surgeon and a dedicated coordinator or navigator, with an expanded team that may involve heart failure specialists, sleep medicine, bariatric medicine, advanced practice providers and anesthesia. Coordinated care pathways and referral networks are described as essential to achieving strong outcomes.
Risk factor modification is treated as a required part of treatment, not an optional add-on. The authors specifically call out obesity, sleep apnea and metabolic disease as modifiable factors that must be addressed alongside the procedure itself.
The paper also highlights increasing interest in combining hybrid ablation with surgical LAA exclusion, which may offer stroke-risk reduction, electrical isolation of the appendage and potential rhythm-control benefits. Importantly, the authors note that anticoagulation generally should continue according to stroke-risk guidelines — LAA clipping alone is not currently considered sufficient justification to discontinue anticoagulation.
Perhaps the most forward-looking section of the consensus addresses the rapid rise of pulsed field ablation (PFA), which has gained attention for its strong safety profile and reduced invasiveness. The authors acknowledge that recent observational studies have shown similar short-term rhythm outcomes between hybrid convergent ablation and PFA, with PFA showing fewer complications and shorter hospital stays. However, they caution that PFA may not fully address advanced epicardial A-fib substrates, since epicardial drivers remain inaccessible to endocardial-only approaches. The authors conclude that a definitive randomized comparison between the two approaches is still needed.
The consensus includes practical recommendations for programs offering hybrid convergent ablation, including: